The fund will invest up to $40m a year to back developers of drugs that will address the growing resistance of diseases to antibiotics.
Denmark-based pharmaceutical firm Novo Holdings launched a $165m impact investment fund yesterday that will back developers of drugs that can combat antimicrobial resistance.
About 20 projects across Europe and the US are expected to receive funding from the vehicle, dubbed Repair Impact Fund, which will provide between $20m and $40m per year in a three-to-five year period.
Repair will focus on the 12 bacterial families identified by the World Health Organization and US Centers for Disease Control and Prevention as…
